Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CNTO 148 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| CNTO 148 50 mg + methotrexate | EXPERIMENTAL | - |
| CNTO 148 100 mg + methotrexate | EXPERIMENTAL | - |
| Placebo + methotrexate | PLACEBO_COMPARATOR | - |
| CNTO 148 50 mg | EXPERIMENTAL | - |
| CNTO 148 100 mg | EXPERIMENTAL | - |
| Placebo | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CNTO 148 | DRUG | 50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 152. |
| Placebo | DRUG | Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 24. |
| Methotrexate (MTX) | DRUG | 6 mg/week to 8 mg/week taken orally (by mouth) from at least 4 weeks before the initial investigational treatment to the completion of assessment at Week 52. |
Inclusion Criteria: * Patients diagnosed with rheumatoid arthritis at least 3 months prior to registration and who are definitely identified as having rheumatoid arthritis, at the time of informed consent, according to the criteria for classification established by the American College of Rheumatol...
Top 20 of 28 competitors
CNTO 148, also known as golimumab, is an investigational small molecule being developed for the treatment of rheumatoid arthritis. It is studied in patients with active rheumatoid arthritis, including those who have not responded adequately to methotrexate therapy.
CNTO 148 targets tumor necrosis factor alpha (TNF-alpha), a key cytokine involved in the inflammatory process of rheumatoid arthritis. By inhibiting TNF-alpha, CNTO 148 aims to reduce inflammation and joint damage associated with the disease.
CNTO 148 is being developed by Johnson & Johnson (NYSE: JNJ). The company is conducting clinical trials to evaluate the safety and efficacy of this drug in patients with rheumatoid arthritis.
CNTO 148 is in Phase 3 clinical development. Two Phase 3 trials have been completed, both focusing on patients with active rheumatoid arthritis. The drug is still investigational and has not been approved for commercial use.
CNTO 148 has been studied in two completed Phase 3 trials: NCT00727987, which enrolled 269 patients with active rheumatoid arthritis despite methotrexate therapy, and NCT00771251, which enrolled 311 patients with active rheumatoid arthritis. Both trials were conducted in Japan.
Yes, CNTO 148 is also known as golimumab. The drug is being developed under the code name CNTO 148, and golimumab is the international nonproprietary name. Both names refer to the same investigational therapy for rheumatoid arthritis.